Key Takeaways The S&P 500 plunged by 1.7% on Friday, Feb. 21, as weak economic data and earnings sent the benchmark index ...

While the details surrounding the new virus are still unfolding, the market's reaction reflects concern over the potential ...

We recently published a list of 10 Firms Kick Off Shortened Trading Week With Impressive Gains. In this article, we are going ...

Moderna, Inc. (NASDAQ:MRNA – Get Free Report) was the recipient of unusually large options trading on Tuesday. Stock investors bought 179,268 call options on the company. This represents an increase ...

The article " Moderna: A Generational Opportunity for Investors in 2025 " first appeared on MarketBeat.

Barclays downgraded shares of Moderna (NASDAQ:MRNA – Free Report) from an overweight rating to an equal weight rating in a report published on Tuesday, Ratings reports. The firm currently has $45.00 ...

EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake ...

Financially, Barclays noted that Moderna’s revenue declined sharply. Fourth-quarter SpikeVax sales came in at $923 million, below Barclays’ estimate of $1.087 billion, and total 2024 product revenue ...

Despite a significant revenue decline, Moderna Inc (MRNA) focuses on strategic program prioritization and cost management to ...

The Dow fell and the Nasdaq Composite rose Nasdaq Friday as the stock market reacted to news of delays to President Donald Trump's reciprocal tariffs.

Live updates on stocks, bonds and other markets, including the Dow Jones Industrial Average, S&P 500 and Nasdaq Composite.

MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...